Objective:Detect the expression level of miRNA-92 a in prostate cancer tissues and cell lines;To evaluate the impact on prostate cancer cell biology behavior;Screening of related target genes of miRNA-92 a.Methods: A total of 100 prostate carcinoma samples and 60 benign prostatic hyperplasia samples were collected from Tianjin institute of urology.Total RNA extracted respectively,the miRNA-92 a expressed in prostate cancer and benign hyperplasia of prostate tissue were detected using the method of RT-qPCR, and the results were statistically analyzed.Selectting prostate cancer cells of PC-3,C4-2,LNCaP and normal prostate epithelial cell line RWPE-1 from tianjin institute of urology. Total RNA extracted respectively,the miRNA-92 a expressed in prostate cancer cell PC-3, C4-2, LNCaP and normal prostate epithelial cell line RWPE-1 were detected using the method of RT-qPCR,and the results were statistically analyzed.Transfect the prostate cancer cells with miRNA-92 a mimic, miRNA-92 a inhibitor and their control,then detect cell proliferation, apoptosis and cell cycle.To explore the role of the abnormal expression of miRNA-92 a in prostate cancer occurrence and development. Using bioinformatics methods, we choose miRanda,TargetScan, PicTar( 3 kind of target gene prediction software) and detect the intersection of genes.Further predict correlation with disease in Search miRò, thus preliminary screening may be associated with tumor target genes.Then we detect the target gene mRNA expression level through the RT-qPCR method. Consequently explore the role of abnormal expression of mi RNA-92 a in prostate cancer occurrence and development.Results: The expression level of miRNA-92 a in prostate tissue were significantly higher than the benign hyperplasia of prostate tissue, and the difference is statistically significant(P<0.01). Using the method of RT-qPCR,we found that the expression level of miRNA-92 a in prostate cancer cell PC-3, C4-2, LNCaP were higher than normal prostate epithelial cell line RWPE-1 and PC-3 has the highest expression level.Then PC-3 cells were chosen for further study.miR-92 a expression level was detected by RT-qPCR after transfection with mimic or inhibitor in PC-3cells.Result showed that the expression level is highest in miR-92 a mimic and lowest in miR-92 a inhibitor group. We observed that the proliferation rate of miR-92 a overexpression cells was dramatically increased.On the contrary,after downregulation of miR-92 a by inhibitor, the proliferation rate of PC-3 cells was dramatically decreased.The apoptosis rate of miR-92 a overexpression cells was dramatically decreased.On the contrary,after downregulation of miR-92 a by inhibitor, the proliferation rate of PC-3 cells was dramatically increased.miR-92 a overexpression cells had a significantly lower percentage of cells in G0/G1 phase and increased percentage of cells in the S phase. On the contrary,after downregulation of miR-92 a by inhibitor, PC-3 cells had a significantly higher percentage of cells in G0/G1 phase and decreased percentage of cells in the S phase. Using bioinformatics methods, we detected 210 intersection of genes,and preliminary screened that there were 10 target genes may be associated with tumor, such as IRS2ã€MTA3ã€BACH1ã€FASLGã€EBAG9ã€SMAD7ã€PTK2ã€POLKã€EZH2 and FLI1.Conclusion: The expression level of miRNA-92 a in prostate tissue were significantly higher than the benign hyperplasia of prostate tissue. The expression level of miRNA-92 a in prostate cancer cell PC-3, C4-2, LNCaP were higher thannormal prostate epithelial cell line RWPE-1. miR-92 a overexpression cells can increase the cell proliferation capacity,restrain cell apoptosis,promote cell from G0/G1 phase to S phase. On the contrary,the downregulation of miR-92 a can decrease the cell proliferation capacity, promote cell apoptosis,restrain cell from G0/G1 phase to S phase. mi R-92 a is as a cancer gene in prostate cancer occurrence and development. With the deepening of the research, once find the direct effect of target genes,we would more comprehensive describe the complex regulatory mechanism. |